A collection of timely studies, news, and treatment options
Genomic Testing Reveals Gene Mutated in Pediatric Melanoma
Comprehensive clinical genomic testing of an adolescent patient, including whole genome sequencing, helped researchers identify mutations in a single gene that drive the most common childhood melanoma.
Identifying a Mechanism of Resistance to BRAF Inhibitors in Melanoma
Melanoma is one of the most aggressive types of skin cancer, but recent advances in targeted therapies have improved the prognosis for many patients. Moffitt Cancer Center researchers have discovered a mechanism by which melanoma cells become resistant to the commonly used drugs that target the BRAF protein and its signaling pathway.
New! BRAF/MEK Inhibitor Combination Improves Survival for Melanoma Patients
A pooled analysis of the COMBI-d and COMBI-v trials revealed a 5-year overall survival (OS) in 34 percent of patients treated with a combination of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily), according to research recently published in the New England Journal of Medicine.